Analysts Offer Predictions for Tcr2 Therapeutics Inc’s FY2018 Earnings (TCRR)

Tcr2 Therapeutics Inc (NASDAQ:TCRR) – Equities researchers at Wedbush issued their FY2018 earnings per share estimates for shares of Tcr2 Therapeutics in a research note issued to investors on Monday, March 11th. Wedbush analyst D. Nierengarten expects that the company will post earnings of ($13.90) per share for the year. Wedbush has a “Outperform” rating and a $28.00 price objective on the stock. Wedbush also issued estimates for Tcr2 Therapeutics’ Q4 2018 earnings at ($0.37) EPS, Q1 2019 earnings at ($0.33) EPS, Q2 2019 earnings at ($0.38) EPS, Q3 2019 earnings at ($0.45) EPS, Q4 2019 earnings at ($0.56) EPS, FY2019 earnings at ($1.72) EPS, FY2020 earnings at ($2.42) EPS, FY2021 earnings at ($2.48) EPS, FY2022 earnings at ($2.29) EPS and FY2023 earnings at ($2.08) EPS.

A number of other research analysts also recently issued reports on TCRR. BMO Capital Markets assumed coverage on shares of Tcr2 Therapeutics in a research report on Monday. They set an “outperform” rating and a $37.00 target price on the stock. Leerink Swann assumed coverage on shares of Tcr2 Therapeutics in a research report on Monday. They set an “outperform” rating on the stock. Svb Leerink assumed coverage on shares of Tcr2 Therapeutics in a research report on Monday. They set an “outperform” rating and a $27.00 target price on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Tcr2 Therapeutics in a research report on Monday. They set a “buy” rating and a $31.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $30.75.

Tcr2 Therapeutics stock opened at $19.08 on Thursday. Tcr2 Therapeutics has a 1 year low of $14.80 and a 1 year high of $25.47.

In related news, major shareholder Upnorth Investment Ltd purchased 200,000 shares of the stock in a transaction dated Tuesday, February 19th. The stock was bought at an average cost of $15.00 per share, with a total value of $3,000,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Morana Jovan-Embiricos purchased 666,667 shares of the stock in a transaction dated Tuesday, February 19th. The stock was bought at an average cost of $15.00 per share, with a total value of $10,000,005.00. The disclosure for this purchase can be found here.

Tcr2 Therapeutics Company Profile

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Featured Article: What is the Coverage Ratio?

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit